American Association for Cancer Research
Browse

Supplementary Tables from Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression

Download (47.86 kB)
journal contribution
posted on 2023-03-31, 01:06 authored by Hirotake Tsukamoto, Koji Fujieda, Masatoshi Hirayama, Tokunori Ikeda, Akira Yuno, Keiko Matsumura, Daiki Fukuma, Kimi Araki, Hiroshi Mizuta, Hideki Nakayama, Satoru Senju, Yasuharu Nishimura

Supplementary Table 1 Demographics and disease characteristics of HNT patients. Supplementary Table 2 Healthy donor information. Supplementary Table 3 The comparison of pathway parameters without covariates between HD and HNT. Supplementary Table 4 Result of multilevel linear models with covariates.

Funding

JSPS KAKENHI

The Takeda Science Foundation

Kumamoto University Advance Research Project A

History

ARTICLE ABSTRACT

IL6 produced by tumor cells promotes their survival, conferring a poor prognosis in patients with cancer. IL6 also contributes to immunosuppression of CD4+ T cell–mediated antitumor effects. In this study, we focused on the impact of IL6 trans-signaling mediated by soluble IL6 receptors (sIL6R) expressed in tumor-bearing hosts. Higher levels of sIL6R circulating in blood were observed in tumor-bearing mice, whereas the systemic increase of sIL6R was not prominent in tumor-bearing mice with myeloid cell–specific conditional deletion of IL6R even when tumor cells produced sIL6R. Abundant sIL6R was released by CD11b+ cells from tumor-bearing mice but not tumor-free mice. Notably, IL6-mediated defects in Th1 differentiation, T-cell helper activity for tumor-specific CD8+ T cells, and downstream antitumor effects were rescued by myeloid-specific deletion of sIL6R. Expression of the T-cell transcription factor c-Maf was upregulated in CD4+ T cells primed in tumor-bearing mice in an IL6-dependent manner. Investigations with c-Maf loss-of-function T cells revealed that c-Maf activity was responsible for IL6/sIL6R-induced Th1 suppression and defective T-cell–mediated antitumor responses. In patients with cancer, myeloid cell–derived sIL6R was also possibly associated with Th1 suppression and c-Maf expression. Our results argued that increased expression of sIL6R from myeloid cells and subsequent c-Maf induction were adverse events for counteracting tumor-specific Th1 generation. Overall, this work provides a mechanistic rationale for sIL6R targeting to improve the efficacy of T-cell–mediated cancer immunotherapy. Cancer Res; 77(9); 2279–91. ©2017 AACR.